Experimental infection and protection against ... - TI Pharma

242 Chapter 11
132. House BL, Hollingdale MR, Sacci JB, Jr., Richie TL. Functional immunoassays
using an in-vitro malaria liver-stage infection model: where do we go from
here? Trends Parasitol 2009; 25:525-533.
133. Morosan S, Hez-Deroubaix S, Lunel F et al. Liver-stage development of
Plasmodium falciparum, in a humanized mouse model. J Infect Dis 2006;
193:996-1004.
134. Chilengi R. Clinical development of malaria vaccines: should earlier trials be
done in malaria endemic countries? Hum Vaccin 2009; 5:627-636.
135. Malkin E, Hu J, Li Z et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric
recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008;
26:6864-6873.
136. Ellis RD, Sagara I, Durbin A et al. Comparing the understanding of subjects
receiving a candidate malaria vaccine in the United States and Mali. Am J Trop
Med Hyg 2010; 83:868-872.
137. Okitsu SL, Silvie O, Westerfeld N et al. A virosomal malaria peptide vaccine
elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a
clinical trial. PLoS One 2007; 2:e1278.
138. Genton B, Pluschke G, Degen L et al. A randomized placebo-controlled phase Ia
malaria vaccine trial of two virosome-formulated synthetic peptides in healthy
adult volunteers. PLoS One 2007; 2:e1018.
139. Wang R, Richie TL, Baraceros MF et al. Boosting of DNA vaccine-elicited gamma
interferon responses in humans by exposure to malaria parasites. Infect Immun
2005; 73:2863-2872.